Claims
- 1. A pharmaceutical composition for oral administration to a human individual, comprising, in a solid dosage form, approximately 0.9 to 1800 mg of a neutral 3:1 hydroxypyrone:gallium complex in which the hydroxypyrone is either unsubstituted or substituted with one to three lower alkyl substituents, a pharmaceutically inert carrier suitable for oral drug administration, and, optionally, an additional active agent.
- 2. The pharmaceutical composition of claim 1 wherein an additional active agent is present.
- 3. The pharmaceutical composition of claim 2, wherein the additional active agent is effective to regulate calcium resorption from bone.
- 4. The pharmaceutical composition of claim 1, comprising approximately 9 to 360 mg of the neutral 3:1 hydroxypyrone:gallium complex.
- 5. The pharmaceutical composition of claim 2, comprising approximately 9 to 360 mg of the neutral 3:1 hydroxypyrone:gallium complex.
- 6. The pharmaceutical composition of claim 3, comprising approximately 9 to 360 mg of the neutral 3:1 hydroxypyrone:gallium complex.
- 7. A pharmaceutical composition for oral administration to a human individual, comprising, in a solid dosage form, approximately 0.9 to 1800 mg of a neutral 3:1 hydroxypyrone:gallium complex in which the hydroxypyrone is selected from the group consisting of 3-hydroxy-4-pyrone, 3-hydroxy-2-methyl-4-pyrone, 3-hydroxy-2-ethyl-4-pyrone, and 3-hydroxy-6-methyl-4-pyrone, a pharmaceutically inert carrier suitable for oral drug administration, and an additional active agent effective to regulate calcium resorption from bone.
- 8. The pharmaceutical composition of claim 7, wherein the hydroxypyrone is selected from the group consisting of 3-hydroxy-2-methyl4-pyrone and 3-hydroxy-2-ethyl4-pyrone.
- 9. The pharmaceutical composition of claim 8, wherein the hydroxypyrone is 3-hydroxy-2-methyl-4-pyrone.
- 10. The pharmaceutical composition of claim 8, wherein the hydroxypyrone is 3-hydroxy-2-ethyl-4-pyrone.
- 11. The pharmaceutical composition of claim 7, wherein the carrier is selected from the group consisting of lactose, starch and dextrin.
CROSS-REFERENCE TO RELATED APPLICATIONS
This is a divisional of U.S. Ser. No. 08/956,175, filed Oct. 22, 1997, allowed, which was a continuation of U.S. Ser. No. 08/655,220, filed Jun. 5, 1996, abandoned, which was a continuation of U.S. Ser. No. 08/505,037, filed Jul. 21, 1995, now issued as U.S. Pat. No. 5,574,027, which was a continuation of U.S. Ser. No. 08/309,624, filed Sep. 21, 1994, abandoned, which was a continuation of U.S. Ser. No. 08/104,623, filed Aug. 11, 1993, abandoned, which was a continuation of Ser. No. 07/782,434, filed Oct. 25, 1991, now issued as U.S. Pat. No. 5,258,376, which was a continuation-in-part of U.S. Ser. No. 07/656,016, filed Feb. 14, 1991, abandoned, which was a continuation of Ser. No. 07/440,277, filed Nov. 22, 1989, abandoned.
US Referenced Citations (11)
Foreign Referenced Citations (3)
Number |
Date |
Country |
2242191 |
Sep 1991 |
GBX |
WO 8901475 |
Feb 1989 |
WOX |
WO 9117751 |
Nov 1991 |
WOX |
Non-Patent Literature Citations (8)
Entry |
Adamson et al. (1975), "Studies on the Antitumor Activity of Gallium Nitrate (NSC-15200) and Other Group IIIa Metal Salts," Cancer Chemotherapy Reports, Part 1, 59(3):599-610. |
Barr et al. (1986), "Effects of the Pyrones, Maltol and Ethyl Maltol, on Iron Absorption from the Rat Small Intestine," J. Pharm. Pharmacol. 39:203-211. |
Bockman et al. (1983), "Abstracts: Bone Metabolism and Cell Biology," Calcified Tissue International 35(4-5):637. |
Farrar et al. (1988), "Tissue Distribution of Gallium Following Administration of the Gallium-Maltol Complex in the Rat," Food Chem. Toxic. 26:523-525. |
Finnegan et al. (1987), "Neutral Water-Soluble Post-Transition Metal . . . ," Inorganic Chemistry 26:2171-2176. |
Foster et al. (1986), "Gallium Nitrate: The Second Metal with Clinical Activity," Cancer Treatment Reports 70(11):1311-1318. |
Hart et al. (1971), "Antitumor Activity and Toxicity of Salts of Inorganic Group IIIa Metals:Aluminum, Gallium, Indium, and Thallium," Proc. Natl. Acad. Sci. USA 68(7):1623-1626. |
Warrell et al., (1989) "Gallium in the Treatment of Hypercalcemia and Bone Metastasis," Important Advances in Oncology, chapter 12 (Philadelphia: J.B. Lippincott Company). |
Divisions (1)
|
Number |
Date |
Country |
Parent |
956175 |
Oct 1997 |
|
Continuations (6)
|
Number |
Date |
Country |
Parent |
655220 |
Jun 1996 |
|
Parent |
505037 |
Jul 1995 |
|
Parent |
309624 |
Sep 1994 |
|
Parent |
104623 |
Aug 1993 |
|
Parent |
782434 |
Oct 1991 |
|
Parent |
440277 |
Nov 1989 |
|